The therapeutic window of tPA, however, is limited to 3–4.5 h post-stroke onset as tPA administration beyond 4.5 h increases the risk of developing edema and hemorrhagic transformation that in turn, is associated with delayed ischemia (Pena et al., 2017). The gene discussed is PLAT; the disease is stroke disorder.